Developing a new generation of inhaled therapies to treat severe respiratory diseases
Our drug-device platform consists of drug aerosol formulations and cutting-edge technology that allows for precise and fast drug delivery into the small airway of the lungs.
A potential alternative to routine injections for those with chronic diseases, which allows for improved efficacy and a better patient experience.
We are advancing a diverse pipeline of inhaled therapies for the treatment of severe respiratory and chronic diseases.
Our lead product candidate is inhaled imatinib (AER-901) for the treatment of pulmonary arterial hypertension. LEARN MORE